<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04879953</url>
  </required_header>
  <id_info>
    <org_study_id>PIPAC</org_study_id>
    <nct_id>NCT04879953</nct_id>
  </id_info>
  <brief_title>Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin</brief_title>
  <official_title>Effect of Pressurised Intraperitoneal Aerosol Chemotherapy on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Francaise de Chirurgie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Francaise de Chirurgie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pressurised intraperitoneal aerosol chemotherapy is a new surgical technique, developed for&#xD;
      the treatment of initially unresectable peritoneal carcinomatosis. The objective of this&#xD;
      study was to compare the results of PIPAC associated with systemic chemotherapy with those of&#xD;
      systemic chemotherapy alone in patients with gastric peritoneal carcinomatosis without&#xD;
      metastasis other than peritoneal, and WHO performance status &lt;3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Overall survival at 6 months from diagnosis of carcinomatosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>6 months</time_frame>
    <description>duration of hospitalization up to 6 months after the diagnosis of carcinomatosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival from the diagnosis of carcinomatosis and from the diagnosis of the primary tumour.</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival throughout the study follow-up from the diagnosis of carcinomatosis and from the diagnosis of the primary tumour.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">46</enrollment>
  <condition>Carcinomatosis, Peritoneal</condition>
  <arm_group>
    <arm_group_label>PIPAC CHEM</arm_group_label>
    <description>PIPAC associated with systemic chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONLY CHEM</arm_group_label>
    <description>systemic chemotherapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PIPAC with systemic chemotherapy</intervention_name>
    <description>PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.</description>
    <arm_group_label>PIPAC CHEM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic chemotherapy alone</intervention_name>
    <description>Intravenous chemotherapy</description>
    <arm_group_label>ONLY CHEM</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consisted of adult patients with adenocarcinoma-type gastric&#xD;
        non-resectable PC, without metastasis other than peritoneal, treated either with PIPAC&#xD;
        administered in alternation with systemic chemotherapy or by systemic chemotherapy alone.&#xD;
        All patients receiving PIPAC in our hospital during the study period were included. The&#xD;
        patients in the group had been treated during the same period and were carefully selected&#xD;
        according to age, general state of health (WHO performance status &lt;3) and absence of&#xD;
        extra-peritoneal metastases so as to match as closely as possible the patients in the PIPAC&#xD;
        group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years or over&#xD;
&#xD;
          -  Patients with adenocarcinoma-type gastric non-resectable péritonéale carcinomatosis.&#xD;
&#xD;
          -  Patients without metastasis other than peritoneal.&#xD;
&#xD;
          -  WHO performance status &lt;3&#xD;
&#xD;
          -  Patients treated either with PIPAC administered in alternation with systemic&#xD;
             chemotherapy (PIPAC_CHEM) or by systemic chemotherapy alone (ONLY_CHEM)&#xD;
&#xD;
          -  Patient informed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients opposed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Arvieux</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grenoble Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUGA</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Association Francaise de Chirurgie</investigator_affiliation>
    <investigator_full_name>Pr Catherine Arvieux</investigator_full_name>
    <investigator_title>Professeur</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

